EXPAREL — Class II drug recall D-168-2013
Terminated recall by Pacira Pharmaceuticals, Inc., reported 2013-03-06, distributed nationwide. Subpotent; bupivacaine
| Recall number | D-168-2013 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Pacira Pharmaceuticals, Inc., San Diego, CA, United States |
| Recall initiated | 2012-12-17 |
| Classified | 2013-02-25 |
| Reported by FDA | 2013-03-06 |
| Terminated | 2013-05-03 |
| Distributed | Nationwide (US) |
| Quantity | 324 vials |
| Reason classes | potency |
Product
EXPAREL (bupivacaine liposome injectable suspension), 1.3%, 266 mg/20 mL (13.3 mg/mL) single use vials, INVESTIGATIONAL USE. For Infiltration Only. Not for any other route of administration. Manufactured by Paelra Pharmaceuticals. Inc., San Diego, California, USA
Reason for recall
Subpotent; bupivacaine
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-168-2013. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.